Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Riyaben P. Patel"'
Autor:
Riyaben P Patel, Pretashini M Somasundram, Lorey K. Smith, Karen E. Sheppard, Grant A. McArthur
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Background Cutaneous melanoma is a lethal form of skin cancer with morbidity and mortality rates highest amongst European, North American and Australasian populations. The developments of targeted therapies (TTs) directed at the oncogene BRA
Externí odkaz:
https://doaj.org/article/42e4ac8011584beba3a1c37d0686c779
Autor:
Karen E. Sheppard, Jane Oliaro, Grant A. McArthur, Nicole M. Haynes, Anthony T. Papenfuss, Carleen Cullinane, Alison Slater, Riyaben P. Patel, Claire Martin, Laura Kirby, Luciano G. Martelotto, Amanda J. Oliver, Peter K.H. Lau, Lydia Lim, Magnus Zethoven, Kelly M. Ramsbottom, Stefano Mangiola, Emily J. Lelliott
Supplementary Figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132b21ff68e5e88683ac5b96348b807a
https://doi.org/10.1158/2326-6066.22543851.v1
https://doi.org/10.1158/2326-6066.22543851.v1
Autor:
Karen E. Sheppard, Jane Oliaro, Grant A. McArthur, Nicole M. Haynes, Anthony T. Papenfuss, Carleen Cullinane, Alison Slater, Riyaben P. Patel, Claire Martin, Laura Kirby, Luciano G. Martelotto, Amanda J. Oliver, Peter K.H. Lau, Lydia Lim, Magnus Zethoven, Kelly M. Ramsbottom, Stefano Mangiola, Emily J. Lelliott
Supplementary Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10cc462866102b136e414540b347056a
https://doi.org/10.1158/2326-6066.22543848
https://doi.org/10.1158/2326-6066.22543848
Autor:
Grant A. McArthur, Riyaben P. Patel, Carleen Cullinane, Claire Martin, Anthony T. Papenfuss, Amanda J Oliver, Kelly M Ramsbottom, Emily J. Lelliott, Nicole M. Haynes, Stefano Mangiola, Peter Lau, Lydia Lim, Jane Oliaro, Laura Kirby, Karen E. Sheppard, Magnus Zethoven, Luciano G. Martelotto, Alison Slater
Publikováno v:
Cancer immunology research. 9(2)
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAFV600 mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combination on an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ff328315e1518bb0eb29a0d897c27ef
https://pubmed.ncbi.nlm.nih.gov/33303574
https://pubmed.ncbi.nlm.nih.gov/33303574
Autor:
Peter Kar Han Lau, Carleen Cullinane, Susan Jackson, Rachael Walker, Lorey K. Smith, Alison Slater, Laura Kirby, Riyaben P. Patel, Bianca von Scheidt, Clare Y. Slaney, Grant A. McArthur, Karen E. Sheppard
Publikováno v:
Cancers
Cancers, Vol 13, Iss 6342, p 6342 (2021)
Cancers; Volume 13; Issue 24; Pages: 6342
Cancers, Vol 13, Iss 6342, p 6342 (2021)
Cancers; Volume 13; Issue 24; Pages: 6342
Simple Summary Adoptive cell transfer (ACT) is a potentially robust treatment option for patients with advanced melanoma that is resistant to immune checkpoint inhibitors. The addition of cyclin-dependent kinase 4/6 inhibitors to combination BRAF-MEK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb9ba8ca4d1c21a092190f481b6f8b9
https://doi.org/10.3390/cancers13246342
https://doi.org/10.3390/cancers13246342